Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
description
Transcript of Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
![Page 1: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/1.jpg)
Decision Making in the Era of Individualized Treatment in
Advanced NSCLC:Highlights From Chicago
![Page 2: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/2.jpg)
Third-Generation EGFR TKIs
![Page 3: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/3.jpg)
![Page 4: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/4.jpg)
![Page 5: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/5.jpg)
EGFR Inhibitors Following Progression on EGFR-Directed
TherapyPreliminary Efficacy Comparison
![Page 6: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/6.jpg)
Antiangiogenic Agents in Advanced NSCLC
![Page 7: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/7.jpg)
![Page 8: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/8.jpg)
![Page 9: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/9.jpg)
First-line Therapy in Advanced NSCLC
![Page 10: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/10.jpg)
![Page 11: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/11.jpg)
![Page 12: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/12.jpg)
![Page 13: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/13.jpg)
![Page 14: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/14.jpg)
Targeting MET in Advanced NSCLC
![Page 15: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/15.jpg)
Global Phase 3 Trial (METLung)* of Onartuzumab
Plus Erlotinib in NSCLC Trial Design
![Page 16: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/16.jpg)
METLung TrialOverall Survival Results
![Page 17: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/17.jpg)
Crizotinib in Advanced MET-amplified NSCLC
Patient Eligibility: NSCLC MET Amplification Cohort
![Page 18: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/18.jpg)
![Page 19: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/19.jpg)
Characteristics of Patients With ALK-Positive Disease; Second- Generation ALK
Inhibitors
![Page 20: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/20.jpg)
![Page 21: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/21.jpg)
ASCEND-1 Trial: Ceritinib in ALK-Positive Advanced NSCLC
Best Percentage Change From Baseline
![Page 22: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/22.jpg)
Immune Checkpoint Inhibitor Therapy in Advanced NSCLC
![Page 23: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/23.jpg)
![Page 24: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/24.jpg)
Abbreviations
![Page 25: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/25.jpg)
Abbreviations (cont)
![Page 26: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/26.jpg)
References
![Page 27: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/27.jpg)
References (cont)
![Page 28: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/28.jpg)
References (cont)
![Page 29: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/29.jpg)
References (cont)
![Page 30: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/30.jpg)
References (cont)
![Page 31: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago](https://reader035.fdocuments.in/reader035/viewer/2022062810/56815b60550346895dc94718/html5/thumbnails/31.jpg)
References (cont)